The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Prescription medicines under evaluation
These applications for new medicines or new uses for existing medicines are currently under evaluation by the TGA. Evaluation does not guarantee registration or PBS entry.
Application types:
- Application type A: applications for a 'new medicine' containing a new active substance (new chemical entity or new biological entity) not currently approved in Australia
- Application type B: applications for a 'new combination', where two or more already approved medicines are combined into a single product
- Application type C: applications for a 'new indication', or additional therapeutic use, for an already approved medicine.
For more information visit Prescription medicines: applications under evaluation.
Loading...
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
- AstraZeneca Pty Ltd (14)
- Janssen-Cilag Pty Ltd (7)
- Accelagen Pty Ltd (5)
- Bristol-Myers Squibb Australia Pty Ltd (5)
- Eli Lilly Australia Pty Ltd (5)
- Seqirus Pty Ltd (5)
- Merck Sharp & Dohme (Australia) Pty Ltd (4)
- AbbVie Pty Ltd (3)
- AFT Pharmaceuticals Pty Ltd (3)
- Amgen Australia Pty Ltd (3)
- GlaxoSmithKline Australia Pty Ltd (3)
- Ipsen Pty Ltd (3)
- Novartis Pharmaceuticals Australia Pty Ltd (3)
- Takeda Pharmaceuticals Australia Pty Ltd (3)
- Astellas Pharma Australia Pty Ltd (2)
- Bayer Australia Ltd (2)
- BeiGene AUS Pty Ltd (2)
- Biogen Australia Pty Ltd (2)
- Boehringer Ingelheim Pty Ltd (2)
- Chiesi Australia Pty Ltd (2)
- Gilead Sciences Pty Ltd (2)
- Norgine Pty Ltd (2)
- Roche Products Pty Ltd (2)
- Vertex Pharmaceuticals Australia Pty Ltd (2)
- AA-Med Pty Ltd (1)
- Acumen Dental Unit Trust (1)
- Amivas Australia Pty Ltd (1)
- Ballia Holdings Pty Ltd (1)
- Fresenius Medical Care Australia Pty Ltd (1)
- Freyr Australia Pty Ltd (1)
- Galderma Australia Pty Ltd (1)
- Guerbet Australia Pty Ltd (1)
- Indivior Pty Ltd (1)
- JACE Pharma Pty Ltd (1)
- Jazz Pharmaceuticals ANZ Pty Ltd (1)
- LEO Pharma Pty Ltd (1)
- Link Medical Products Pty Ltd T/A Link Pharmaceuticals (1)
- Merz Australia Pty Ltd (1)
- Moderna Australia Pty Ltd (1)
- Nexo Pharmaceuticals Pty Ltd (1)
- Novo Nordisk Pharmaceuticals Pty Ltd (1)
- Pfizer Australia Pty Ltd (1)
- Phebra Pty Ltd (1)
- PTC THERAPEUTICS AUSTRALIA PTY LIMITED (1)
- Reach Pharmaceuticals Pty Ltd (1)
- Sanofi-Aventis Australia Pty Ltd (1)
- Specialised Therapeutics Pharma Pty Ltd (1)
- Taiho Pharma Oceania Pty Ltd (1)
- UCB Australia Pty Ltd T/A UCB Pharma Division of UCB Australia (1)
Search
111 result(s) found, displaying 1 to 25
-
Feb-2025Prescription medicine evaluationActive ingredient: pembrolizumab.
-
Feb-2025Prescription medicine evaluationActive ingredient: tirzepatide.
-
Feb-2025Prescription medicine evaluationActive ingredient: teplizumab.
-
Jan-2025Prescription medicine evaluationActive ingredient: Brentuximab vedotin.
-
Jan-2025Prescription medicine evaluationActive ingredient: apadamtase alfa.
-
Jan-2025Prescription medicine evaluationActive ingredient: delgocitinib.
-
Jan-2025Prescription medicine evaluationActive ingredient: belantamab mafodotin.
-
Jan-2025Prescription medicine evaluationActive ingredient: acalabrutinib maleate monohydrate.
-
Jan-2025Prescription medicine evaluationActive ingredient: daratumumab.
-
Jan-2025Prescription medicine evaluationActive ingredient: mirvetuximab soravtansine.
-
Jan-2025Prescription medicine evaluationActive ingredient: Influenza virus haemagglutinin.
-
Jan-2025Prescription medicine evaluationActive ingredient: durvalumab.
-
Jan-2025Prescription medicine evaluationActive ingredient: Seladelpar lysine dihydrate.
-
Jan-2025Prescription medicine evaluationActive ingredient: sodium thiosulfate anhydrous.
-
Jan-2025Prescription medicine evaluationActive ingredient: tofersen.
-
Jan-2025Prescription medicine evaluationActive ingredient: buprenorphine.
-
Jan-2025Prescription medicine evaluationActive ingredient: SARS-CoV-2 spike NTD-RBD mRNA.
-
Jan-2025Prescription medicine evaluationActive ingredient: guselkumab.
-
Dec-2024Prescription medicine evaluationActive ingredient: cefiderocol sulfate tosilate.
-
Dec-2024Prescription medicine evaluationActive ingredient: Influenza virus.
-
Dec-2024Prescription medicine evaluationActive ingredient: darolutamide.
-
Dec-2024Prescription medicine evaluationActive ingredient: asciminib hydrochloride.
-
Nov-2024Prescription medicine evaluationActive ingredient: cabozantinib (S)-malate.
-
-
Nov-2024Prescription medicine evaluationActive ingredient: trastuzumab deruxtecan.
Pages
- Current page 1
- Page 2
- Page 3
- Page 4
- Page 5
- Next page Next ›
- Last page Last »